Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2

Status

Completed 40Unknown 11Terminated 6Active not recruiting 5Withdrawn 3Recruiting 3Not yet recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 5

Conditions

Multiple Myeloma 52Recurrence 6Neoplasms, Plasma Cell 5Neoplasms 3Immunoglobulin Light-chain Amyloidosis 3Waldenstrom Macroglobulinemia 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Paraproteinemias 2Lymphoma, Mantle-Cell 2Lymphoma 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Rhabdoid Tumor 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Multi-centric Castleman's Disease 1Macular dystrophy, corneal type 1 1Lymphoproliferative Disorders 1Lymphoma, B-Cell 1Lymphadenopathy 1Leukemia, Myeloid, Acute 1Leukemia 1HIV Infections 1

Interventions

Dexamethasone 13Lenalidomide 11daratumumab 5carfilzomib 5Bortezomib 5Calcium Dobesilate 4Whole-Body Irradiation 3Tacrolimus 3Mycophenolic Acid 3Melphalan 3Cyclophosphamide 3ixazomib 2isatuximab 2fludarabine phosphate 2fludarabine 2belantamab mafodotin 2Etoposide 2venetoclax 1thymoglobulin 1selinexor 1pomalidomide 1poly ICLC 1citarinostat 1Transplantation 1Thalidomide 1Sirolimus 1Rituximab 1Positron Emission Tomography Computed Tomography 1Pharmaceutical Preparations 1Peripheral Blood Stem Cell Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Active not recruiting × Neoplasms, Plasma Cell × Bortezomib × Clear all
NCT00871013 2026-05-11

Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy

University of Arkansas

Phase 2 Active not recruiting
160 enrolled
Plasma cell

Neoplasms, Plasma Cell

NCT04151667 2026-03-11

Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
33 enrolled 11 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04751877 2026-02-10

Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).

Poitiers University Hospital

Phase 3 Active not recruiting
270 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01208662 2026-01-22

DFCI 10-106

Dana-Farber Cancer Institute

Phase 3 Active not recruiting
729 enrolled 29 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04052880 2025-07-20

Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM

Icahn School of Medicine at Mount Sinai

Phase 2 Active not recruiting
17 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡